We have collected information about Brain-Targeted Delivery Of Tempol-Loaded Nanoparticles For Neurological Disorders for you. Follow the links to find out details on Brain-Targeted Delivery Of Tempol-Loaded Nanoparticles For Neurological Disorders.
https://www.ncbi.nlm.nih.gov/pubmed/20158436
Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. Carroll RT(1), Bhatia D, Geldenhuys W, Bhatia R, Miladore N, Bishayee A, Sutariya V. Author information: (1)Department of Pharmaceutical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, Ohio 44272, USA.Author: Richard T. Carroll, Deepak Bhatia, Werner Geldenhuys, Ruchi Bhatia, Nicholas Miladore, Anupam Bishay...
https://www.researchgate.net/publication/41450371_Brain-targeted_delivery_of_Tempol-loaded_nanoparticles_for_neurological_disorders
Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders Article in Journal of Drug Targeting 18(9):665-74 · February 2010 with 47 Reads How we measure 'reads'
https://www.tandfonline.com/doi/abs/10.3109/10611861003639796
Feb 14, 2002 · Brain-targeted Tempol-loaded poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) conjugated with a transferrin antibody (OX 26) were developed using the nanoprecipitation method.These NPs may have utility in treating neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease.Author: Richard T. Carroll, Deepak Bhatia, Werner Geldenhuys, Ruchi Bhatia, Nicholas Miladore, Anupam Bishay...
https://link.springer.com/chapter/10.1007/978-3-030-06115-9_15
Mar 12, 2019 · To overcome these problems, nanomedicines which are based on noninvasive strategies are an emerging trend for brain-targeted drug delivery. The advantages of nanoparticles such as small size, lipophilicity, target specificity, and controlled delivery of drug satisfy the requisites for brain targeting.Author: Sunita Lahkar, Malay K. Das
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245440/
Brain-Targeted Delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer ... but comes as a disadvantage when attempting to treat brain-related disorders . ... Bhatia R, Miladore N, Bishayee A, et al. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target. 2010; 18 (9):665–74. doi: 10 ...Author: Aditya Grover, Anjali Hirani, Yashwant Pathak, Vijaykumar Sutariya
https://www.tandfonline.com/doi/abs/10.3109/1061186X.2011.589435
May 15, 2015 · Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. Richard T. Carroll et al. Journal of Drug Targeting. Volume 18, 2010 - Issue 9. Published online: 4 Oct 2010. review. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease.Author: Werner Geldenhuys, Thomas Mbimba, Thong Bui, Kimberly Harrison, Vijaykumar Sutariya
https://link.springer.com/article/10.1208/s12249-014-0165-0
Aug 19, 2014 · Brain-Targeted Delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer. ... Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target. 2010;18(9):665–74. ... Grover, A., Hirani, A., Pathak, Y. et al. Brain-Targeted Delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain ...Author: Aditya Grover, Anjali Hirani, Yashwant Pathak, Vijaykumar Sutariya
https://health.usnews.com/doctors/nicholas-miladore-838531
Dr. Nicholas Miladore is an orthopedic surgeon in Kalamazoo, Michigan and is affiliated with one hospital. He has been in practice between 3-5 years. Orthopedic surgeons diagnose and treat ...
https://www.researchgate.net/publication/231222991_Brain_Drug_Delivery_Systems_for_Neurodegenerative_Disorders
Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major ...
https://www.mdpi.com/2227-9059/6/3/92/htm
Age-related macular degeneration (AMD) is one of the leading causes of blindness in the United States, affecting approximately 11 million patients. AMD is caused primarily by an upregulation of vascular endothelial growth factor (VEGF). In recent years, aflibercept injections have been used to combat VEGF. However, this treatment requires frequent intravitreal injections, leading to low ...Author: Shannon J. Kelly, Anjali Hirani, Vishal Shahidadpury, Aum Solanki, Kathleen Halasz, Sheeba Varghese ...
Searching for Brain-Targeted Delivery Of Tempol-Loaded Nanoparticles For Neurological Disorders?
You can just click the links above. The data is collected for you.
